Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers.
Prothon S, Wählby Hamrén U, Tehler U, Yoon E, Forsman H, Arfvidsson C, Aggarwal A, Chen Y. Prothon S, et al. Among authors: wahlby hamren u. Drug Des Devel Ther. 2019 Nov 12;13:3845-3853. doi: 10.2147/DDDT.S215170. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31814707 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator.
Singh D, Balaguer V, Astbury C, Wählby-Hamrén U, Jimenez E, Seoane B, Villarroel C, Lei A, Aggarwal A, Psallidas I. Singh D, et al. Among authors: wahlby hamren u. Respir Res. 2020 Sep 9;21(Suppl 1):102. doi: 10.1186/s12931-020-01347-7. Respir Res. 2020. PMID: 32907566 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies.
Balaguer V, Albayaty M, Jimenez E, Wählby-Hamrén U, Astbury C, Seoane B, Malice MP, Lei A, Aggarwal A, Psallidas I. Balaguer V, et al. Among authors: wahlby hamren u. Respir Res. 2020 Sep 9;21(Suppl 1):212. doi: 10.1186/s12931-020-01474-1. Respir Res. 2020. PMID: 32907575 Free PMC article. Clinical Trial.
Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator.
Jimenez E, Astbury C, Albayaty M, Wählby-Hamrén U, Seoane B, Villarroel C, Pujol H, Bermejo MJ, Aggarwal A, Psallidas I. Jimenez E, et al. Among authors: wahlby hamren u. Respir Res. 2020 Sep 9;21(Suppl 1):211. doi: 10.1186/s12931-020-01470-5. Respir Res. 2020. PMID: 32907576 Free PMC article. Clinical Trial.
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
Singh D, Beier J, Astbury C, Belvisi MG, Da Silva CA, Jauhiainen A, Jimenez E, Lei A, Necander S, Smith JA, Wählby Hamrén U, Xin W, Psallidas I. Singh D, et al. Among authors: wahlby hamren u. Eur Respir J. 2022 Apr 7;59(4):2100972. doi: 10.1183/13993003.00972-2021. Print 2022 Apr. Eur Respir J. 2022. PMID: 34503985 Free PMC article. Clinical Trial.
Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects.
Holmberg AA, Weidolf L, Necander S, Bold P, Sidhu S, Pelay-Gimeno M, de Ligt RAF, Verheij ER, Jauhiainen A, Psallidas I, Wählby Hamrén U, Prothon S. Holmberg AA, et al. Among authors: wahlby hamren u. Drug Metab Dispos. 2022 Feb;50(2):150-157. doi: 10.1124/dmd.121.000632. Epub 2021 Dec 1. Drug Metab Dispos. 2022. PMID: 34853068
A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation.
Cheung SYA, Parkinson J, Wählby-Hamrén U, Dota CD, Kragh ÅM, Bergenholm L, Vik T, Collins T, Arfvidsson C, Pollard CE, Tomkinson HK, Hamrén B. Cheung SYA, et al. Among authors: hamren b, wahlby hamren u. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):365-381. doi: 10.1007/s10928-018-9589-6. Epub 2018 May 7. J Pharmacokinet Pharmacodyn. 2018. PMID: 29736890 Clinical Trial.
20 results